`
`
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`
`
`C.A. No. ____________
`
`
`
`X
`:
`:
`:
`:
`:
`:
`:
`:
`:
`:
`:
`:
`:
`:
`X
`
`
`
`
`NOVARTIS PHARMACEUTICALS
`CORPORATION, NOVARTIS AG,
`NOVARTIS PHARMA AG, NOVARTIS
`INTERNATIONAL PHARMACEUTICAL
`LTD. and LTS LOHMANN THERAPIE-
`SYSTEME AG
`
` Plaintiffs,
`
`
`
`
`v.
`
`PAR PHARMACEUTICAL, INC.
`
` Defendant.
`
`
`
`
`
`
`COMPLAINT FOR PATENT INFRINGEMENT
`
`Plaintiffs Novartis Pharmaceuticals Corporation, Novartis AG, Novartis Pharma
`
`AG, Novartis International Pharmaceutical Ltd. and LTS Lohmann Therapie-Systeme AG
`
`(hereinafter “Plaintiffs”), for their Complaint against defendant Par Pharmaceutical, Inc. allege
`
`as follows:
`
`NATURE OF ACTION
`
`1.
`
`This is an action for patent infringement.
`
`PARTIES
`
`2.
`
`Plaintiff Novartis Pharmaceuticals Corporation (“NPC”) is a corporation
`
`organized and existing under the laws of the State of Delaware, having a principal place of
`
`business at 59 Route 10, East Hanover, New Jersey 07936.
`
`
`ME1 16333346v.1
`
`
`
`Case 1:13-cv-01467-RGA Document 1 Filed 08/22/13 Page 2 of 7 PageID #: 2
`
`
`
`3.
`
`Plaintiff Novartis AG (“Novartis AG”) is a corporation organized and
`
`existing under the laws of Switzerland, having an office and place of business at Lichtstrasse 35,
`
`CH-4056 Basel, Switzerland.
`
`4.
`
`Plaintiff Novartis Pharma AG (“Pharma AG”) is a corporation organized
`
`and existing under the laws of Switzerland, having an office and place of business at Lichtstrasse
`
`35, CH-4056 Basel, Switzerland.
`
`5.
`
`Plaintiff Novartis International Pharmaceutical Ltd. (“NIP”) is a
`
`corporation organized and existing under the laws of Bermuda, having an office and place of
`
`business at 131 Front Street, Hamilton HM12, Bermuda.
`
`6.
`
`Plaintiff LTS Lohmann Therapie-Systeme AG (“LTS”) is a corporation
`
`organized and existing under the laws of Germany, having an office and place of business at
`
`Lohmannstraße 2, D-56626 Andernach, Germany.
`
`7.
`
`On information and belief, defendant Par Pharmaceutical, Inc. (“Par”) is a
`
`corporation organized and existing under the laws of the State of Delaware, having an office and
`
`place of business at One Ram Ridge Road, Spring Valley, New York 10977.
`
`JURISDICTION AND VENUE
`
`8.
`
`This action arises under the patent laws of the United States of America.
`
`This Court has jurisdiction over the subject matter of this action under 28 U.S.C. §§ 1331,
`
`1338(a), 2201 and 2202.
`
`9.
`
`On information and belief, Par is incorporated in Delaware and has
`
`purposely availed itself of the rights and benefits of Delaware law and this Court.
`
`10.
`
`On information and belief, Par is in the business of manufacturing,
`
`marketing, importing into the United States and selling pharmaceutical drug products, including
`
`
`ME1 16333346v.1
`
`2
`
`
`
`Case 1:13-cv-01467-RGA Document 1 Filed 08/22/13 Page 3 of 7 PageID #: 3
`
`
`
`generic drug products. On information and belief, Par directly or through its affiliates and agents
`
`markets and sells drug products throughout the United States and in this judicial district, and has
`
`purposely availed itself of the rights and benefits of Delaware law and this Court.
`
`11.
`
`This Court has personal jurisdiction over Par by virtue of, inter alia, the
`
`above-mentioned facts.
`
`12.
`
`Venue is proper in this Court pursuant to 28 U.S.C. §§ 1391(b) and (c)
`
`and 28 U.S.C. § 1400(b).
`
`CLAIM FOR RELIEF – PATENT INFRINGEMENT
`
`13.
`
`Plaintiff NPC holds an approved new drug application (“NDA”) No. 22-
`
`083 for Exelon®
` Patch (rivastigmine transdermal system or extended release film) (4.6 mg/24 hr,
`
`9.5 mg/24 hr and 13.3 mg/24 hr dosage strengths), which patch contains the active ingredient
`
`rivastigmine. Exelon®
` Patch (4.6 mg/24 hr and 9.5 mg/24 hr dosage strengths) was approved by
`
`the United States Food and Drug Administration (“FDA”) on July 6, 2007, and Exelon® Patch
`
`(13.3 mg/24 hr dosage strength) was approved by the FDA on August 31, 2012. Exelon® Patch
`
`is indicated for the treatment of mild to moderate dementia of the Alzheimer’s type and mild to
`
`moderate dementia associated with Parkinson’s disease. Exelon®
` Patch (4.6 mg/24 hr, 9.5 mg/24
`
`hr and 13.3 mg/24 hr dosage strengths) is sold in the United States by Plaintiff NPC.
`
`14.
`
`Rivastigmine is known chemically as (S)-N-ethyl-3-[(1-
`
`dimethylamino)ethyl]-N-methylphenyl-carbamate.
`
`15.
`
`Plaintiffs Novartis AG and LTS are the owners of United States Letters
`
`Patent No. 6,335,031 (“the ‘031 patent”). The ‘031 patent was duly and legally issued on
`
`January 1, 2002.
`
`
`ME1 16333346v.1
`
`3
`
`
`
`Case 1:13-cv-01467-RGA Document 1 Filed 08/22/13 Page 4 of 7 PageID #: 4
`
`
`
`16.
`
`The ‘031 patent claims pharmaceutical compositions, inter alia,
`
`comprising: (a) a therapeutically effective amount of (S)-N-ethyl-3-[(1-dimethylamino)ethyl]-N-
`
`methylphenyl-carbamate in free base or acid addition salt form; (b) about 0.01 to about 0.5
`
`percent by weight of an antioxidant, based on the weight of the composition, and (c) a diluent or
`
`carrier, as well as transdermal devices and methods of stabilizing (S)-N-ethyl-3-[(1-
`
`dimethylamino)ethyl]-N-methylphenyl-carbamate in free base or acid addition salt form. A true
`
`copy of the ‘031 patent is attached hereto as Exhibit A.
`
`17.
`
`The ‘031 patent was initially assigned to Novartis AG and LTS Lohmann
`
`Therapie-Systeme GmbH & Co. KG, which subsequently changed its legal form to become
`
`Plaintiff LTS.
`
`18.
`
`On information and belief, Par submitted to the FDA an abbreviated new
`
`drug application (“ANDA”) under the provisions of 21 U.S.C. § 355(j) seeking approval to
`
`engage in the commercial manufacture, use, and sale of a rivastigmine transdermal system, 13.3
`
`mg/24 hr dosage strength (“Par’s ANDA Product”) before the expiration of the ‘031 patent.
`
`19.
`
`On information and belief, Par made and included in its ANDA a
`
`certification under 21 U.S.C. § 355(j)(2)(A)(vii)(IV) that, in its opinion and to the best of its
`
`knowledge, the ‘031 patent is invalid and/or will not be infringed.
`
`20.
`
`By filing its ANDA under 21 U.S.C. § 355(j) for the purpose of obtaining
`
`approval to engage in the commercial manufacture, use, or sale of Par’s ANDA Product before
`
`the expiration of the ‘031 patent, Par has committed an act of infringement under 35 U.S.C. §
`
`271(e)(2).
`
`
`ME1 16333346v.1
`
`4
`
`
`
`Case 1:13-cv-01467-RGA Document 1 Filed 08/22/13 Page 5 of 7 PageID #: 5
`
`
`
`21.
`
`On information and belief, when Par filed its ANDA, it was aware of the
`
`‘031 patent and that the filing of its ANDA with the request for its approval prior to the
`
`expiration of the ‘031 patent was an act of infringement of that patent.
`
`22.
`
`On information and belief, the commercial manufacture, use, offer for
`
`sale, sale and/or importation of Par’s ANDA Product will infringe one or more claims of the
`
`‘031 patent.
`
`23.
`
`On information and belief, the commercial manufacture of Par’s ANDA
`
`Product will involve direct infringement of the ‘031 patent. On information and belief, this will
`
`occur at Par’s active behest, and with Par’s intent, knowledge and encouragement. On
`
`information and belief, Par will actively induce, encourage and abet this infringement with
`
`knowledge that it is in contravention of the rights under the ‘031 patent.
`
`24.
`
`Plaintiffs are entitled to the relief provided by 35 U.S.C. § 271(e)(4),
`
`including an order of this Court that the effective date of any approval of the aforementioned
`
`ANDA relating to Par’s ANDA Product be a date that is not earlier than January 8, 2019, the
`
`expiration date of the ‘031 patent, and an award of damages for any commercial sale or use of
`
`Par’s ANDA Product and any act committed by Par with respect to the subject matter claimed in
`
`the ‘031 patent, which act is not within the limited exclusions of 35 U.S.C. § 271(e)(1).
`
`25.
`
`On information and belief, Par has taken and continues to take active steps
`
`towards the commercial manufacture, use, offer for sale, sale and/or importation of Par’s ANDA
`
`Product, including seeking approval of that product under Par’s ANDA.
`
`26.
`
`There is a substantial and immediate controversy between Plaintiffs and
`
`Par concerning the ‘031 patent. Plaintiffs are entitled to declaratory judgment under 28 U.S.C.
`
`
`ME1 16333346v.1
`
`5
`
`
`
`Case 1:13-cv-01467-RGA Document 1 Filed 08/22/13 Page 6 of 7 PageID #: 6
`
`
`
`§§ 2201 and 2202 that Par will infringe and/or induce infringement of one or more claims of the
`
`‘031 patent.
`
`PRAYER FOR RELIEF
`
`WHEREFORE, Plaintiffs respectfully request the following relief:
`
`A.
`
`Judgment that Par has infringed and induced infringement of one or more
`
`claims of the ‘031 patent by filing the aforesaid ANDA relating to Par’s rivastigmine transdermal
`
`system, 13.3 mg/24 hr dosage strength;
`
`B.
`
`A permanent injunction restraining and enjoining Par and its officers,
`
`agents, attorneys and employees, and those acting in privity or concert with it, from engaging in
`
`the commercial manufacture, use, offer to sell, or sale within the United States, or importation
`
`into the United States, of a rivastigmine transdermal system, 13.3 mg/24 hr dosage strength, as
`
`claimed in the ‘031 patent;
`
`C.
`
`An order that the effective date of any approval of the aforementioned
`
`ANDA relating to Par’s rivastigmine transdermal system, 13.3 mg/24 hr dosage strength, be a
`
`date that is not earlier than the expiration of the right of exclusivity under the ‘031 patent;
`
`D.
`
`Declaratory judgment that the commercial manufacture, use, offer for sale,
`
`sale and/or importation of Par’s rivastigmine transdermal system, 13.3 mg/24 hr dosage strength,
`
`will infringe one or more claims of the ‘031 patent and that Par will induce infringement of one
`
`or more claims of the ‘031 patent;
`
`
`
`
`
`E.
`
`Damages from Par for the infringement and inducement of infringement of
`
`the ‘031 patent;
`
`
`
`
`
`
`
`
`
`F.
`
`G.
`
`
`ME1 16333346v.1
`
`The costs and reasonable attorney fees of Plaintiffs in this action; and
`
`Such other and further relief as the Court may deem just and proper.
`
`6
`
`
`
`Case 1:13-cv-01467-RGA Document 1 Filed 08/22/13 Page 7 of 7 PageID #: 7
`
`
`
`
`
`Dated: August 22, 2013
`
`
`
`
`
`
`
`McCARTER & ENGLISH, LLP
`
`
`
`
`
`
`
`
`/s/ Daniel M. Silver
`Michael P. Kelly (#2295)
`Daniel M. Silver (#4758)
`Renaissance Centre
`405 N. King Street, 8th Floor
`Wilmington, Delaware 19801
`(302) 984-6300
`mkelly@mccarter.com
`dsilver@mccarter.com
`
`Attorneys for Plaintiffs
`
`
`Of Counsel:
`
`Nicholas N. Kallas
`Filko Prugo
`FITZPATRICK, CELLA, HARPER & SCINTO
`1290 Avenue of the Americas
`New York, New York 10104-3800
`(212) 218-2100
`nkallas@fchs.com
`fprugo@fchs.com
`
`
`
`
`ME1 16333346v.1
`
`7